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Introduction: There is evidence that inherited genetic variation affects both testicular
germ cell tumor (TGCT) treatment outcome and risks of late-complications arising
from cisplatin-based chemotherapy. Using a candidate gene approach, we examined
associations of three genes involved in the cisplatin metabolism pathway, GSTP1,
COMT, and TPMT, with TGCT outcome and cisplatin-induced neurotoxicity. Materials
and Methods: Our study population includes a subset of patients (n = 137) from a
genome-wide association study at the University of Pennsylvania that evaluates inherited
genetic susceptibility to TGCT. All patients in our study had at least one course of
cisplatin-based chemotherapy with at least 1 year of follow-up. A total of 90 markers in
GSTP1, COMT, and TPMT and their adjacent genomic regions (±20 kb) were analyzed for
associations with refractory TGCT after first course of chemotherapy, progression-free
survival (PFS), overall survival (OS), peripheral neuropathy, and ototoxicity. Results:
After adjustment for multiple comparisons, one Single nucleotide polymorphism (SNP),
rs2073743, in the flanking region (±20 kb) of COMT was associated with refractory
TGCT after initial chemotherapy. This SNP lies within the intron region of the Armadillo
Repeat gene deleted in Velco-Cardio-Facial syndrome (ARVCF ). The G allele of rs2073743
predisposed patients to refractory disease with a relative risk of 2.6 (95% CI 1.1, 6.3;
P = 0.03). Assuming recessive inheritance, patients with the GG genotype had 22.7 times
higher risk (95% CI 3.3, 155.8; P = 0.04) of developing refractory disease when compared
to those with the GC or CC genotypes. We found no association of our candidate genes
with peripheral neuropathy, ototoxicity, PFS and OS. Discussion: This is the first study to
suggest that germline genetic variants of ARVCF may affect TGCT outcome. The result of
this study is hypothesis generating and should be validated in future studies.
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INTRODUCTION
Testicular germ cell tumor (TGCT) is the most common solid
malignancy that affects men between the ages 15 and 35 (National
Cancer Institute, 2011). Cisplatin-based chemotherapy is the
standard treatment for patients with metastatic disease and is
highly effective with a 5-year survival rate that approaches 95%
(Jemal et al., 2008). Since its introduction in the 1970s, there
is a large and growing population of long-term survivors with
TGCT. However, cisplatin-based chemotherapy causes peripheral
neuropathy and ototoxicity in approximately 20–30% of long-
term TGCT survivors and risk of these adverse events increases
with higher cumulative dose of cisplatin (Fung and Vaughn,
2011).
Germline genetic variation affects both TGCT outcome
and late-complications arising from cisplatin-based treatment.
Single nucleotide polymorphisms (SNPs) of the bleomycin
hydrolase (de Haas et al., 2008) (BLMH) and the high
plasminogen-activator inhibitor 1 (de Haas et al., 2010) (PAI-1)
genes have been shown to impact survival among TGCT patients
(de Haas et al., 2008, 2010). Variants in glutathione S-transferase
pi (GSTP1), which encodes an enzyme that detoxifies chemother-
apeutic agents by conjugating reactive electrophiles to glu-
tathione (Mannervik et al., 1985), appear to be important in the
development of long-term peripheral neuropathy and ototoxic-
ity in adult TGCT patients (Oldenburg et al., 2007a,b). Similarly,
SNPs of thiopurine S-methyltransferase (TPMT) and catechol
O-methyltransferase (COMT), which encodes enzymes that
metabolize thiopurine drugs (Weinshilboum, 2006) and cate-
cholamine containing chemical via methylation (Weinshilboum,
2006), respectively, predispose the pediatric population to
increased risk of hearing loss (Ross et al., 2009) after cisplatin
therapy.
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In an attempt to validate and extend previous findings
regarding effects of germline genetic variation on cancer
outcome and treatment-related toxicities via their effects on
drug metabolism (Coate et al., 2010), we used a candidate gene
approach to investigate the associations of GSTP1, COMT, and
TPMT, three genes involved in the cisplatin metabolism pathway,
with treatment outcome and cisplatin-induced neurotoxicity. We
hypothesized that genetic variants in GSTP1, COMT, and TPMT
that confer higher intracellular concentration of cisplatin or its
metabolites are associated with lower rates of TGCT recurrence
and higher incidence of cisplatin-related neurotoxicity. To test
this hypothesis, we evaluated a selected panel of SNPs in GSTP1,
COMT, andTPMT with cancer outcome, ototoxicity, and periph-
eral neuropathy in an existing cohort of men with TGCT who
have received at least one course of cisplatin-based chemotherapy.
MATERIALS AND METHODS
STUDY POPULATION
Our study cohort is derived from a subset of TGCT case sub-
jects enrolled into an ongoing case-control study designed to
evaluate inherited genetic susceptibility to TGCT. Details of
the parent case-control study have been described previously
(Kanetsky et al., 2009, 2011) In brief, case subjects were recruited
from a network of hospitals, including the Hospital of the
University of Pennsylvania (HUP), University of Pennsylvania
Cancer Network, Fox Chase Cancer Center, and also from the
Pennsylvania and New Jersey State Cancer Registries. Only men
between ages 18 and 50 years with pathologically confirmed
TGCT were included, and those with human immunodeficiency
virus, Klinefelter’s or Down syndrome were excluded. All enrolled
patients with TGCT who underwent cisplatin chemotherapy at
HUP were potentially eligible for the current study. A total of
137 patients had at least one course of cisplatin-based chemother-
apy, at least 1 year of follow-up since initiation of cisplatin-based
chemotherapy and at least one clinical consultation with an
oncologist at HUP and are included in the final analytic cohort.
The study was approved by the institutional review board at
the University of Pennsylvania. All patients gave written informed
consent.
GENOTYPING FOR SNPs OF GSTP1, COMT, AND TPMT
All study participants had previously been genotyped using
the Affymetrix Genome-Wide Human SNP Array 6.0 platform;
details of genotyping efforts and quality control measures have
previously been reported (Kanetsky et al., 2009, 2011). A total
of 90 SNP markers with genotype call rates ≥ 90% that mapped
to the genomic regions (±20 kb) of COMT, TPMT, and GSTP1
(43, 44, and 3 markers, respectively) were used for analysis. A
complete listing of annotated SNP markers are available from the
authors by request.
TREATMENT RESPONSE ASSESSMENT
A complete review of medical records was performed to
abstract information regarding treatment response, patient
demographics, tumor characteristics, and treatment informa-
tion. Monitoring for treatment response included both sero-
logic [alpha fetal protein (AFP) and beta human chorionic
gonadotropin (β-HCG)] and radiographic studies (plain radio-
graphy, computed tomography, or magnetic resonance imaging).
We evaluated three treatment efficacy endpoints: (1) refractory
disease after first course of chemotherapy, (2) progression-free
survival (PFS), and (3) overall survival (OS). Clinical remission
was defined as disappearance of all tumors by radiographic meth-
ods and normalization of both AFP and β-HCG level for at least
4 weeks after completion of first course of chemotherapy. Cancer
recurrence was defined as initial clinical remission with subse-
quent development of disease evidenced by radiographic imaging
or serology. Refractory disease was defined as persistent radio-
graphic or serologic evidence of disease after initial course of
chemotherapy.
NEURO- AND OTO-TOXICITY ASSESSMENT
We collected information regarding cisplatin-related periph-
eral neuropathy and ototoxicity from patients using a self-
administered mailed questionnaire instrument. We adapted 12
of the 15 questions from the Michigan Neuropathy Screening
Instrument (MNSI) (Moghtaderi et al., 2006) for assessment of
peripheral neuropathy. For ototoxicity, we used 10 questions from
an existing screening survey of hearing problem at the National
Institute on Deafness and other Communications Disorders
(Fung and Vaughn, 2011) with inclusion of one additional
question about the presence of tinnitus.
In addition to mailing the questionnaire to all 137 patients
in our study cohort, we distributed it on site to patients
(n = 31) who had routine clinic visits at the Hospital of
the University of Pennsylvania from July 2010 to June 2011.
To improve the response rate, we sent reminder letters to
non-responders 8 weeks after initial mailing of the question-
naire. At 12 weeks, phone calls were made to all remaining
non-responders.
Patients were defined as having peripheral neuropathy if their
MNSI score was two or greater. The threshold was based on
the results of a MNSI validation study in subjects with dia-
betic peripheral neuropathy (Feldman et al., 1994). Subjects were
defined as having ototoxicity if they answered “yes” to three or
more of the 11 questions.
STATISTICAL ANALYSIS
We summarized the baseline characteristics of our popula-
tion using means and standard deviations for continuous
variables (age at diagnosis, age at initiation of chemother-
apy, initial cisplatin dose, and cumulative life-time cisplatin
dose) and proportions for categorical variables [genetically
inferred race from GWAS, histology, International Germ Cell
Consensus Classification (IGCCC), primary site of tumor, and
type of chemotherapy]. We compared the baseline characteristics
between cohorts with and without completed toxicity question-
naires using Fisher’s exact test for categorical variables and t-test
for continuous variables. We used logistic regression models
to investigate associations between baseline characteristics and
peripheral neuropathy, ototoxicity, and refractory disease after
first course of chemotherapy. We conducted a time to event anal-
ysis using a Cox proportional hazards model to assess the effects
of baseline covariates on PFS and OS.
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We summarized themajor andminor allele frequencies of each
SNP marker and determined if their genotypic distributions were
in Hardy–Weinberg equilibrium.
We studied associations of SNP markers with endpoints
assuming co-dominant, recessive, and dominant genetic models
using Pearson’s chi-squared tests. We accounted formultiple com-
parisons by adjusting the p-values of these associations using the
method of Benjamini and Hochberg (1995). We used multivari-
able logistic regression models to assess associations of genetic
markers with peripheral neuropathy and ototoxicity, after adjust-
ing for race, IGCCC prognostic group, primary site of disease,
type of chemotherapy, and cumulative dose of cisplatin. To assess
the association between each SNP and refractory disease after
initial chemotherapy, we used multivariable logistic regression
models with adjustment for race, IGCCC prognostic group, pri-
mary site of disease, type of chemotherapy, and dose of cisplatin
during first course of chemotherapy. Since refractory disease
accounts for less than 10% of all treatment outcomes, estimates
from the logistic regression model are interpreted and reported as
relative risks.
To assess the association between each SNP and PFS or OS,
we used Cox proportional hazardsmodels. In these time-to-event
models, patients contributed to the analyses from the initiation
of chemotherapy until date of last follow-up or death in the OS
model with inclusion of cancer recurrence as an additional cen-
soring event in the PFS model. In the PFS model, we adjusted
for race, IGCCC prognostic group, primary site of disease, type
of chemotherapy, and dose of cisplatin during first course of
chemotherapy. In the OS model, we adjusted for race, IGCCC
prognostic group, primary site of disease, type of chemotherapy,
and cumulative dose of cisplatin. We report hazard ratios (HR)
and corresponding 95% CI from the Cox models.
All statistical analyses were performed using Stata 12
(StataCorp LP, Texas, 2011).
RESULTS
BASELINE CHARACTERISTICS OF PATIENTS
Baseline characteristics of all 137 patients and the subset of 66
patients (48.2%) who completed the toxicity questionnaire are
given in Table 1. As expected, whites account for the majority of
patients in both groups (86.8% in the entire cohort and 93.9%
in the questionnaire subgroup) and the mean age at TGCT diag-
nosis is similar (31.0 years and 32.7 years, respectively). Tumor
characteristics are similar between the groups: the predominant
histology is non-seminoma (81.7% in the entire cohort and
75.8% in the questionnaire subset), the primary site of presen-
tation is the testicle (89.0% and 90.9%, respectively), and the
majority of tumors are classified as good prognosis at initia-
tion of chemotherapy by the IGCCC criteria (68.6% and 80.3%,
respectively). For both groups, bleomycin, etoposide, and cis-
platin (BEP) is the most common initial chemotherapy regimen
(62.0% of the entire group and 59.1% of the questionnaire subset)
and the mean cumulative cisplatin dose (mg/m2) is comparable
among them (410.9 and 404.5, respectively).
In general, patients who completed the toxicity question-
naire are similar to the non-responders. There are no differences
in terms of histology, primary site of TGCT, types of initial
chemotherapy, or cumulative cisplatin dose administered (P >
0.05). However, those who completed the questionnaire were
older at the time of diagnosis of TGCT (P = 0.03) and hence
at initiation of chemotherapy (P = 0.02). A larger proportion of
non-responders were non-whites (19.7% versus 6.1%, P = 0.02)
and also had poor risk disease (32.4% versus 12.1%, P = 0.01)
when compared to those who completed the questionnaire.
PERIPHERAL NEUROPATHY AND OTOTOXICITY
Among the 66 patients who completed the toxicity questionnaire,
25 (37.9%) and 30 (45.5%) of them reported peripheral neu-
ropathy and ototoxicity, respectively (Table 2). Patients who were
diagnosed with TGCT at an older age were more likely to report
developing peripheral neuropathy (OR = 3.1, 95% CI 1.5, 6.4 per
10 year increase in age) as were patients with higher cumulative
life-time cisplatin dose (OR = 1.6, 95% CI 1.1, 2.2 per 100mg/m2
increased in dose). Those with non-seminoma (OR = 0.3, 95%
CI 0.1, 0.8) and BEP (OR = 0.3, 95% CI 0.1, 0.95) as initial
treatment had statistically significantly reduced risk of peripheral
neuropathy compared to those with seminoma or treatment with
etoposide and cisplatin (EP), respectively. Regarding ototoxicity,
only higher cumulative life-time cisplatin dose (OR = 1.5, 95%
CI 1.1, 2.1 per 100mg/m2 increased in dose) and total cisplatin
dose (OR = 2.1, 95% CI 1.03, 4.3 per 100mg/m2 increased in
dose) during initial chemotherapy increased this risk significantly.
TREATMENT OUTCOME
In our cohort of 137 patients, 11 (8.0%) of them had refrac-
tory disease after initial course of chemotherapy and 126 (92%)
of them achieved clinical remission. Among those with remis-
sion, 30 (23.8%) of them experienced disease relapse after a
mean follow-up time of 46.8 months, with a total of eight deaths
within the entire cohort. Table 3 shows that extra-gonadal pri-
mary (RR = 9.7, 95%CI 2.5, 37.3), intermediate/poor risk cancer
(RR = 28.2, 95% CI 3.5, 228.7), and initial therapy with etopo-
side/ifosamide/cisplatin (VIP) (RR = 135.0, 95% CI 6.7, 2733.6)
were statistically significantly associated with refractory disease.
Patients with non-seminoma (HR = 3.4, 95% CI 1.03–10.9),
extra-gonadal primary (HR = 3.5, 95% CI 1.7, 7.3), interme-
diate/poor risk cancer (HR = 4.1, 95% CI 2.2, 7.7), initial VIP
(HR = 27.7, 95% CI 7.9, 96.7), and higher total cisplatin dose
during initial chemotherapy (HR = 1.5, 95% CI 1.01–2.3 per
100mg/m2 increased in dose) all had worse PFS. Patients with
extra-gonadal primary (HR = 5.5, 95% CI 1.3, 22.9), intermedi-
ate/poor risk cancer (HR = 17.7, 95%CI 2.2, 143.5), VIP as initial
chemotherapy (HR = 255.7, 95% CI 12.2, 5367.1), and higher
cumulative life-time cisplatin dose (HR = 1.6, 95% CI 1.2, 2.1
per 100mg/m2 increased in dose) had worse OS.
ASSOCIATIONS OF VARIANTS IN COMT, TPMT, AND GSTP1WITH
PERIPHERAL NEUROPATHY, OTOTOXICITY, AND TREATMENT
OUTCOMES
We found statistically significant associations of four SNP mark-
ers (rs4646316, rs4380755, rs5008499, and rs6591256) in or
near COMT, TPMT, and GSTP1 with neuropathy and five SNP
markers (rs3788306, rs12189790, rs17420046, rs6938294, and
rs6912842) with ototoxicity at the nominal p-value of 0.05.
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Table 1 | Baseline characteristics of patients.
All patients (n = 137) Patients with Patients without p-valuea
completed toxicity completed toxicity
questionnaire (n = 66) questionnaire (n = 71)
DEMOGRAPHICS
Race White 119 86.8% 62 93.9% 57 80.3% 0.02
Black 5 3.7% 0 0.0% 5 7.0%
Hispanic 4 2.9% 0 0.0% 4 5.7%
Asian 5 3.7% 3 4.6% 2 2.8%
Other 4 2.9% 1 1.5% 3 4.2%
Mean age at diagnosis ±
SD (years)
31.0 ± 8.5 32.7 ± 8.6 29.5 ± 8.3 0.03
CHARACTERISTICS OF TGCT
Histology Seminoma 25 18.3% 16 24.2% 9 12.7% 0.12
Non-seminoma 112 81.7% 50 75.8% 62 87.3%
Primary site at presentation Testicle 122 89.0% 60 90.9% 62 87.3% 0.24
Retroperitoneum 6 4.4% 4 6.1% 2 2.8%
Mediastinum 9 6.6% 2 3.0% 7 9.9%
IGCCC prognosis groupb Good 94 68.6% 53 80.3% 41 57.7% 0.01
Intermediate 11 8.0% 5 7.6% 6 8.5%
Poor 31 22.6% 8 12.1% 23 32.4%
Unknown 1 0.7% 0 0.0% 1 1.4%
CHARACTERISTICS OF CHEMOTHERAPY
Type of initial chemotherapy EP 46 33.6% 26 39.4% 20 28.2% 0.35
BEP 85 62.0% 39 59.1% 46 64.8%
TIP 1 0.7% 0 0.0% 1 1.4%
VIP 4 2.9% 1 1.5% 3 4.2%
Other 1 0.7% 0 0.0% 1 1.4%
Mean initial total cisplatin
dose ± SD (mg/m2)c
345.3 ± 80.4 337.9 ± 80.0 352.1 ± 82.6 0.30
Mean cumulative cisplatin
dose ± SD (mg/m2)d
410.9 ± 169.2 404.5 ± 166.8 416.9 ± 172.4 0.67
Mean age at initiation of
chemotherapy ± SD (year)
31.5 ± 9.1 33.4 ± 9.3 29.7 ± 8.5 0.02
SD, standard deviation; TGCT, testicular germ cell tumor; EP, etoposide and cisplatin; BEP, bleomycin, etoposide, and cisplatin; TIP, paclitaxel, ifosamide, and cisplatin;
VIP, etoposide, ifosamide, and cisplatin.
aP-values for comparison of baseline characteristics between cohorts with and without completed toxicity questionnaires. Fisher’s exact test used for categorical
variables and t-test used for continuous variables.
bIGCCC prognosis group of TGCT at initiation of first course of chemotherapy.
cMean total cisplatin dose administered during first course of chemotherapy.
d Mean cumulative life-time cisplatin dose administered by the end of last follow-up visit.
Italic values indicate p ≤ 0.05.
However, after correcting for multiple testing, these associations
did not retain statistical significance (Table 4).
Nine SNPs in or near COMT, TPMT, and GSTP1 had a statis-
tically significant association with refractory disease after initial
chemotherapy at the nominal p-value of 0.05 (Table 5). After
correcting for multiple testing, we found that recessive inheri-
tance of the G allele of rs2073743 confers increased risk (RR =
22.7, 95% CI 3.3, 155.8) of refractory disease after first course of
chemotherapy. However, this association did not retain statistical
significance after adjustment for race, IGCCC, primary site of dis-
ease at diagnosis, type of initial chemotherapy, and total dose of
cisplatin during first course of chemotherapy.
The G allele of rs2073743 had a frequency of 22.76% in the
cohort and its genotypic distribution was in Hardy–Weinberg
proportions (P = 0.46). This allele was present in 40.91% of
patients with refractory disease compared to 21.14% of those
with clinical remission after initial chemotherapy, predisposing
patients to refractory disease with a relative risk of 2.6 (95% CI
of 1.1, 6.3; P = 0.03).
We found statistically significant association of six SNPs
(rs1042781, rs2073743, rs2531706, rs5748505, rs6518598, and
rs4380755) in or near COMT, TPMT, and GSTP1 with PFS
and six SNPs (rs366148, rs2239395, rs1858770, rs12158214,
rs887200, and rs372534) with OS at the nominal p-value of 0.05
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Table 2 | Risk factors for development of peripheral neuropathy and ototoxicity of 66 patients who completed the toxicity questionnaire.
Peripheral neuropathy Ototoxicity
Yes N (%) No N (%) OR 95% CI P-value Yes N (%) No N (%) OR 95% CI P-value
AGE AT DIAGNOSISa
Mean ± SD (year) 37.0 ± 8.7 30.0 ± 7.4 3.1 1.5, 6.4 <0.01 33.6 ± 7.9 31.9 ± 9.1 1.3 0.7, 2.3 0.44
RACE
White (n = 62) 23 (92.0) 39 (95.1) 1.0 – – 30 (100) 32 (88.9) 1.0 – –
Non-white (n = 4) 2 (8.0) 2 (4.9) 1.7 0.2,12.9 0.61 0 (0.0) 4 (11.1) 1.0 NA NA
PRIMARY SITE
Testicle (n = 60) 22 (88.0) 38 (92.7) 1.0 – – 26 (86.7) 34 (94.4) 1.0 – –
Extra-gonadal (n = 6) 3 (12.0) 3 (7.3) 1.7 0.3, 9.3 0.53 4 (13.3) 2 (5.6) 2.6 0.4, 15.4 0.29
HISTOLOGY
Seminoma (n = 16) 10 (40.0) 6 (14.6) 1.0 – – 9 (30.0) 7 (19.4) 1.0 – –
Non-seminoma (n = 50) 15 (60.0) 35 (85.4) 0.3 0.1, 0.8 0.02 21 (70.0) 29 (80.6) 0.6 0.2, 1.8 0.32
IGCCC PROGNOSIS GROUP
Good (n = 53) 20 (80.0) 33 (80.5) 1.0 – – 23 (76.7) 30 (83.3) 1.0 – –
Intermediate/poor (n = 13) 5 (20.0) 8 (19.5) 1.0 0.3, 3.6 0.96 7 (23.3) 6 (16.7) 1.5 0.5, 5.2 0.50
TYPES OF INITIAL CHEMOTHERAPY
EP (n = 26) 14 (56.0) 12 (29.3) 1.0 – – 12 (40.0) 14 (38.9) 1.0 – –
BEP (n = 39) 11 (44.0) 28 (68.3) 0.3 0.1, 0.95 0.04 17 (56.7) 22 (61.1) 0.9 0.3, 2.4 0.84
VIP (n = 1) 0 (0) 1 (2.4) NA NA NA 1 (3.3) 0 (0) NA NA NA
INITIAL TOTAL CISPLATIN DOSEb
Mean ± SD (mg/m2) 360.0 ± 81.6 324.4 ± 73.4 2.0 0.9, 4.1 0.08 360.0 ± 56.3 319.4 ± 88.9 2.1 1.03, 4.3 0.04
CUMULATIVE CISPLATIN DOSEc
Mean ± SD (mg/m2) 476.0 ± 173.9 361.0 ± 148.1 1.6 1.1, 2.2 0.01 460.0 ± 188.6 358.3 ± 131.7 1.5 1.1, 2.1 0.02
OR, odds ratio; CI, confidence interval; SD, standard deviation; NA, not applicable; EP, etoposide and cisplatin; BEP, bleomycin, etoposide, and cisplatin;
VIP, etoposide, ifosamide, and cisplatin.
aOdds ratio per increase of 10 years of age.
bOdds ratio per increase of 100 mg/m2 of total cisplatin dose administered during first course of chemotherapy.
cOdds ratio per increase of 100 mg/m2 of cumulative life-time cisplatin dose administered by the end of last follow-up visit.
Bold-italic values indicate p ≤ 0.05.
(Table 6). In particular, patients with the recessive GG genotype
of rs2073743 had an inferior PFS with a HR of 3.6 (95% CI 1.1,
11.7) when compared to those with the GC or CC genotypes.
However, after correcting the p-values for multiple testing, none
of these associations remained statistically significant.
DISCUSSION
This study examined the association between three genes involved
in cisplatin metabolism, GSTP1, COMT, and TPMT, with TGCT
outcomes and cisplatin-induced ototoxicity and peripheral neu-
ropathy. We found one SNP (rs2073743) in the flanking region
(±20 kb) of COMT that was associated with refractory TGCT
after initial chemotherapy. This SNP lies within the intron region
of the Armadillo Repeat gene deleted in Velo-Cardio-Facial syn-
drome (ARVCF). This is the first study to show that germline
genetic variants of ARVCF may affect TGCT outcome.
Although there is no functional information for SNP
rs2073743, we hypothesize that it may affect disease risk by alter-
ing the expression of the ARVCF gene. ARVCF gene is a member
of the p120 catenin family of proteins (Reintsch et al., 2008)
and its over-expression has been shown to cause disruption of
cell adhesion (Reintsch et al., 2008), which may facilitate can-
cer progression. A recent study by Lin et al. (2011) reported that
the dominant inheritance of the minor T allele of rs5993891 of
ARVCF is associated with a decrease in prostate cancer specific
mortality (HR = 0.21, 95% CI 0.07, 0.61). Therefore, it is pos-
sible that SNP rs2073743 of ARVCF may predispose patients to
higher risk of refractory TGCT by inhibition of cell adhesion,
which consequently causes more aggressive tumor biology.
In contrast, SNP rs2073743 may be a marker for genetic varia-
tions in COMT that affect the risk of refractory TGCT by altering
the level of S-adenosyl-L-methionine (AdoMet) and the con-
centration of estrogen and its metabolites. COMT encodes a
methyltransferase that is critical for the metabolism of endoge-
nous catecholamine containing chemicals and catechol drugs
with AdoMet being its intermediary metabolite (Weinshilboum,
2006). There is some evidence to suggest that cisplatin may inter-
act synergistically with AdoMet (Ochoa et al., 2009). Ochoa and
colleagues found that administration of both AdoMet and cis-
platin causes a 3.0–6.2-fold increase in frequency of renal toxicity
in mice while cisplatin alone causes only moderate toxicity and
administration AdoMet by itself did not result in any nephro-
toxicity (Ochoa et al., 2009). Consequently, it is possible that
increased activity of the COMT enzyme causes a decrease in the
concentration of AdoMet, which may in turn lead to decreased
cytotoxic activity of cisplatin.
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Table 4 | Association of genetic variants that reached a nominal p-value of 0.05 with peripheral neuropathy and ototoxicity among 66 patients
who completed the toxicity questionnaire.
Gene (SNP) Genotype Case N (%) Control N (%) Univariate model Multivariate modela
Odds ratio (95% CI) p-value Odds ratio (95% CI) p-value
Pe
rip
he
ra
ln
eu
ro
pa
th
y
COMT
rs4646316 Co-dominant genetic model
T/T 0 (0) 3 (7.3) 0.1 (0.02,0.8) 0.03 0.1 (0.01,0.7) 0.03
T/C 9 (37.5) 23 (56.1) 0.3 (0.1,0.9) 0.03 0.3 (0.1,0.9) 0.03
C/C 15 (62.5) 15 (36.6) 1.0 – 1.0 –
Dominant genetic model
T/- 9 (37.5) 26 (63.4) 0.4 (0.1,0.98) 0.05 0.3 (0.1,0.98) 0.05
C/C 15 (62.5) 15 (36.6) 1.0 – 1.0 –
TPMT
rs4380755 Co-dominant genetic model
T/T 1 (4.3) 0 (0) 8.7 (1.02,74.1) 0.05 18.9 (1.1,323.8) 0.04
T/C 9 (39.1) 8 (21.1) 2.9 (1.01,8.6) 0.05 4.3 (1.1,18.0) 0.04
C/C 13 (56.5) 30 (78.9) 1.0 – 1.0 –
rs5008499 Co-dominant genetic model
T/T 1 (4.5) 0 (0) 15.0 (1.5,152.0) 0.02 14.4 (0.97,212.0) 0.05
T/C 8 (36.4) 6 (15.0) 3.9 (1.2,12.3) 0.02 3.8 (0.99,14.6) 0.05
C/C 13 (59.1) 34 (85.0) 1.0 – 1.0 –
GSTP1
rs6591256 Dominant genetic model
G/- 12 (52.2) 30 (76.9) 0.3 (0.1,0.99) 0.05 0.3 (0.1,1.1) 0.08
A/A 11 (47.8) 9 (23.1) 1.0 – 1.0 –
O
to
to
xi
ci
ty
COMT
rs3788306 Dominant genetic model
G/- 20 (74.1) 17 (48.6) 3.0 (1.02,9.0) 0.05 4.9 (1.3−18.8) 0.02
A/A 7 (25.9) 18 (51.4) 1.0 – 1.0 –
TPMT
rs12189790 Co-dominant genetic model
T/T 0 (0) 0 (NA) 13.8 (1.1,90.1) 0.04 20.6 (1.5,277.1) 0.02
T/C 13 (43.3) 7 (19.4) 3.2 (1.19.5) 0.04 4.5 (1.2,16.6) 0.02
C/C 17 (56.7) 29 (80.6) 1.0 – 1.0 –
Dominant genetic model
T/- 13 (43.3) 7 (19.4) 3.2 (1.1,9.5) 0.04 4.5 (1.2,16.6) 0.02
C/C 17 (56.7) 29 (80.6) 1.00 – 1.0 –
rs17420046 Co-dominant genetic model
T/T 1 (3.3) 2 (5.6) 0.1 (0.0,0.6) 0.02 0.01 (0.0,0.3) 0.01
T/G 1 (3.3) 12 (33.3) 0.2 (0.1,0.8) 0.02 0.1 (0.03,0.6) 0.01
G/G 28 (93.3) 22 (61.1) 1.0 – 1.0 –
Dominant genetic model
T/- 2 (6.7) 14 (38.9) 0.1 (0.02,0.6) 0.01 0.1 (0.01,0.4) 0.01
G/G 28 (93.3) 22 (61.1) 1.0 – 1.0 –
rs6938294 Co-dominant genetic model
G/G 1 (3.3) 2 (5.7) 0.04 (0.0,0.6) 0.02 0.01 (0.0,0.3) 0.01
G/A 1 (3.3) 12 (34.3) 0.2 (0.1,0.8) 0.02 0.1 (0.03,0.6) 0.01
A/A 28 (93.3) 21 (60.0) 1.0 – 1.0 –
Dominant genetic model
G/- 2 (6.7) 14 (40.0) 0.1 (0.02,0.5) 0.01 0.04 (0.01,0.4) 0.01
A/A 28 (93.3) 21 (60.0) 1.0 – 1.0 –
rs6912842 Dominant genetic model
T/- 13 (43.3) 7 (19.4) 3.2 (1.1,9.5) 0.04 4.5 (1.2,16.6) 0.02
G/G 17 (56.7) 29 (80.6) 1.0 – 1.0 –
CI, confidence interval.
aAdjusted for race, IGCCC, primary site of cancer, type of chemotherapy administered, and cumulative life-time cisplatin dose administered.
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Table 5 | Association of genetic variants that reached a nominal p-value of 0.05 with refractory disease after initial chemotherapy among 137
patients in the study cohort.
Gene (SNP) Genotype Yes N (%) No N (%) Univariate model Multivariate modela
Relative risk (95% CI) p-value Relative risk (95% CI) p-value
COMT
rs2073743 Co-dominant genetic model
G/G 3 (27.3) 2 (1.6) 8.8 (1.2,65.8) 0.04 4.7 (0.3,69.4) 0.25
G/C 3 (27.3) 48 (39.0) 3.0 (1.1,8.1) 0.04 2.2 (0.6,8.3) 0.25
C/C 5 (45.4) 73 (59.3) 1.0 − 1.0 −
Recessive genetic model
G/G 3 (27.3) 2 (1.6) 22.7 (3.3,155.8) < 0.01b 21.8 (1.01,470.7) 0.05c
C/- 8 (72.7) 121 (98.4) 1.0 − 1.0 −
rs4646316 Co-dominant genetic model
T/T 0 (0) 6 (4.9) 0.01 (0.0,0.6) 0.03 0.001 (0.0,0.3) 0.02
T/C 1 (9.1) 59 (48.0) 0.1 (0.01,0.8) 0.03 0.03 (0.02,0.5) 0.02
C/C 10 (90.9) 58 (47.1) 1.0 − 1.0 −
Dominant genetic model
T/- 1 (9.1) 65 (52.8) 0.1 (0.01,0.7) 0.02 0.03 (0.001,0.7) 0.02
C/C 10 (90.9) 58 (47.2) 1.0 − 1.0 −
rs366148 Dominant genetic model
A/- 3 (27.3) 9 (7.3) 4.8 (1.07,21.1) 0.04 2.6 (0.3,21.5) 0.4
G/G 8 (72.7) 114 (92.7) 1.0 − 1.0 −
rs2531706 Dominant genetic model
G/- 5 (45.5) 91 (76.5) 0.3 (0.1,0.9) 0.03 0.2 (0.02,0.97) 0.05
A/A 6 (54.5) 28 (23.5) 1.0 − 1.0 −
rs5748505 Dominant genetic model
T/- 4 (36.4) 88 (69.8) 0.3 (0.1,0.9) 0.03 0.2 (0.05,1.2) 0.09
C/C 7 (63.6) 38 (30.2) 1.0 − 1.0 −
rs1034564 Recessive genetic model
A/A 3 (30.0) 7 (5.8) 7.0 (1.533.0) 0.01 4.7 (0.5,42.8) 0.2
G/- 7 (70.0) 114 (94.2) 1.0 − 1.0 −
TPMT
rs12524744 Co-dominant genetic model
T/T 0 (0) 0 (0) 20.6 (1.3,319.3) 0.03 20.1 (0.5,822.4) 0.10
T/C 4 (40.0) 16 (12.8) 4.5 (1.2,17.9) 0.03 4.5 (0.7,28.7) 0.10
C/C 6 (60.0) 109 (87.2) 1.0 − 1.0 −
Dominant genetic model
T/- 4 (40.0) 16 (12.8) 4.5 (1.2,17.9) 0.03 4.5 (0.7,28.7) 0.10
C/C 6 (60.0) 109 (87.2) 1.0 − 1.0 −
rs9396834 Co-dominant genetic model
C/C 5 (45.4) 15 (11.9) 6.6 (1.1,40.8) 0.04 5.0 (0.6,45.0) 0.15
C/T 3 (27.3) 62 (49.2) 2.6 (1.03,6.4) 0.04 2.2 (0.7,6.7) 0.15
T/T 3 (27.3) 49 (38.9) 1.0 − 1.0 −
Recessive genetic model
C/C 5 (45.5) 15 (11.9) 6.2 (1.7,22.71) 0.01 4.4 (0.7,26.1) 0.10
T/- 6 (54.5) 111 (88.1) 1.0 − 1.0 −
GSTP1
rs6591256 Co-dominant genetic model
G/G 0 (0) 10 (8.7) 0.1 (0.01,0.9) 0.05 0.04 (0.01,0.93) 0.05
G/A 4 (36.4) 67 (58.3) 0.3 (0.1,0.97) 0.05 0.2 (0.04,0.96) 0.05
A/A 7 (63.6) 38 (33.0) 1.0 − 1.0 −
CI, confidence interval.
aAdjusted for race, IGCCC, primary site of disease at diagnosis, type of chemotherapy administered, and total dose of cisplatin received during initial chemotherapy.
bCorrected p-value for multiple testing: 0.04.
cCorrected p-value for multiple testing: 0.72.
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Table 6 | Association of genetic variants that reached a nominal p-value of 0.05 with progression-free and overall survival among 137 patients
in the study cohort.
Gene (SNP) Genotype Mean PFS/OS (mo) Univariate model Multivariate modela
Hazard ratio (95% CI) p-value Hazard ratio (95% CI) p-value
Pr
og
re
ss
io
n-
fr
ee
su
rv
iv
al
COMT
rs10427871 Co-dominant genetic model
G/G NA 45.7 (2.5, 845.7) 0.01 9469.3 (62.7, 1429366.1) < 0.01
G/A 7.7 6.8 (1.6, 29.1) 0.01 97.3 (7.9, 1195.6) < 0.01
A/A 48.4 1.0 − 1.0 −
Dominant genetic model
G/- 7.7 6.8 (1.6, 29.1) 0.01 97.3 (7.9, 1195.6) < 0.01
A/A 48.4 1.0 − 1.0 −
rs2073743 Recessive genetic model
G/G 43.9 3.6 (1.1, 11.7) 0.03 1.2 (0.3, 4.6) 0.84
C/- 46.2 1.0 − 1.0 −
rs2531706 Dominant genetic model
G/- 47.5 0.5 (0.3, 0.9) 0.03 0.4 (0.2, 0.8) 0.01
A/A 42.6 1.0 − 1.0 −
rs5748505 Dominant genetic model
T/- 51.1 0.5 (0.3, 0.95) 0.03 0.5 (0.2, 0.9) 0.02
C/C 38.3 1.0 − 1.0 −
rs6518598 Dominant genetic model
A/- 51.8 0.5 (0.3, 0.9) 0.02 0.4 (0.2, 0.8) 0.01
C/C 38.8 1.0 − 1.0 −
TPMT
rs4380755 Recessive genetic model
T/T 2.0 61.8 (5.6, 681.9) < 0.01 273.9 (16.8, 4464.8) < 0.01
C/- 49.0 1.0 − 1.0 −
O
ve
ra
ll
su
rv
iv
al
COMT
rs366148 Co-dominant genetic model
A/A 11.2 49.1 (3.4, 716.6) < 0.01 15.9 (0.3, 880.5) 0.18
A/G 50.0 7.0 (1.8, 26.8) < 0.01 4.0 (0.5, 29.7) 0.18
G/G 61.2 1.0 − 1.0 −
Dominant genetic model
A/- 46.7 8.3 (2.0, 34.8) < 0.01 4.0 (0.5, 29.7) 0.18
G/G 61.2 1.0 − 1.0 −
rs2239395 Dominant genetic model
G/- 51.0 7.7 (1.8, 32.3) 0.01 8.9 (1.4, 57.4) 0.02
T/T 59.6 1.0 − 1.0 −
rs1858770 Co-dominant genetic model
C/C 11.2 30.5 (1.5, 608.1) 0.03 26.7 (0.3, 2150.4) 0.14
C/A 53.2 5.5 (1.2, 24.7) 0.03 5.2 (0.6, 46.4) 0.14
A/A 59.8 1.0 − 1.0 −
Dominant genetic model
C/- 48.5 6.6 (1.3, 32.6) 0.02 5.2 (0.6, 46.4) 0.14
A/A 59.8 1.0 − 1.0 −
rs12158214 Recessive genetic model
T/T 42.4 5.4 (1.04, 27.8) 0.05 NA NA
C/- 61.4 1.0 − 1.0 −
rs887200 Dominant genetic model
G/- 46.9 4.1 (1.02, 16.4) 0.05 4.0 (0.8, 18.7) 0.08
A/A 62.5 1.0 − 1.0 −
(Continued)
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Table 6 | Continued
Gene (SNP) Genotype Mean PFS/OS (mo) Univariate model Multivariate modela
Hazard ratio (95% CI) p-value Hazard ratio (95% CI) p-value
O
ve
ra
ll
su
rv
iv
al
TPMT
rs372534 Co-dominant genetic model
G/G 10.5 26.5 (1.8, 389.7) 0.02 4.7 (0.3, 74.3) 0.27
G/A 54.0 5.2 (1.4, 19.7) 0.02 2.2 (0.5, 8.6) 0.27
A/A 62.6 1.0 − 1.0 −
Recessive genetic model
G/G 10.5 46.9 (4.2, 528.3) < 0.01 0.6 (0.03, 12.9) 0.73
A/- 59.9 1.0 − 1.0 −
PFS, progression-free survival; OS, overall survival; CI, confidence interval; NA, not applicable.
aPFS: hazard ratio adjusted for race, IGCCC, type of chemotherapy administered, and cumulative life-time cisplatin dose administered by the end of last follow-up
visit; OS: hazard ratio adjusted for race, IGCCC, primary site of cancer, type of chemotherapy administered, and cumulative life-time cisplatin dose administered by
the end of last follow-up visit.
TGCTs are thought to develop from totipotent primordial
germ cells (Sinisi et al., 2003) and there is evidence to sug-
gest that a combination of high gonadotropin level coupled with
unbalanced androgen and estrogen level may be a key event
for TGCT development and progression (Garolla et al., 2005).
Fotsis et al. (1994) reported that 2-methoxyoestriol, which is an
endogenous estrogen metabolite, inhibits angiogenesis and sup-
presses tumor growth in mice. Since COMT degrades catechol
metabolites from estradiol and estrone to methylated compounds
(Weinshilboum, 2006), genetic variation of COMT may be impli-
cated in the development and progression of TGCT. Recently,
Ferlin et al. (2010) studied 17 polymorphic markers in 11 genes
involved in hormone metabolism and reported that the minor A
allele of rs11205 in the 17 β-hydroxysteroid dehydrogenase type
4 gene (HSD17B4), which is essential for metabolism of estrone
to estradiol, is associated with higher risk of TGCT (OR = 2.73,
95% CI 1.47, 7.06). In the same study, however, they found
no association of rs4680 of COMT with development of TGCT
(Ferlin et al., 2010).
Since the association between rs2073743 with refractory dis-
ease was no longer statistically significant after adjusting for
race, IGCCC, primary site of disease at diagnosis, type of ini-
tial chemotherapy, and total dose of cisplatin during first course
of chemotherapy, we examined if any of these covariates are
associated with rs2073743. Interestingly, we found that patients
with the G/G genotype at this marker have higher odds of
having both extra-gonadal primary (OR = 14.63, 95% CI 2.22,
96.35) and initial chemotherapy with VIP (OR = 45.00, 95%
CI 2.77, 730.57). However, we found no such association with
race, IGCCC, and total dose of cisplatin. Therefore, patients with
rs2073742 may have genetic predisposition to more aggressive
TGCT at presentation. This may instead explain their increased
risk of refractory disease after initial chemotherapy. On the
contrary, since VIP is commonly used for treatment of extra-
gonadal TGCT, it simply may be a marker for extra-gonadal
disease. Finally, our failure to detect any association of rs2073743
with PFS or OS may result from inadequate statistical power
due to small sample size (n = 137) and the relatively short
mean follow-up time of 46.8 months within the context of the
excellent 5-year survival rate of TGCT, which approaches 95%
(Fung and Vaughn, 2011).
Our study confirms the known established prognostic factors
for TGCT, including both IGCCC risk groups and primary site
of disease presentation, thus suggesting that our results are inter-
nally valid. Based on the original study (n = 5862) that validated
the IGCCC (Wanderas et al., 2006), the 5-year OS for good,
intermediate, and poor risk metastatic GCT are 91%, 79% and
48%, respectively while the 5-year PFS for these respective prog-
nostic groups are 89%, 75%, and 41%. Our study showed slightly
better 5-year OS for all risk groups (good risk: 98.7%, interme-
diate risk: 87.5%, and poor risk: 76.1%) but comparable 5-year
PFS except for that of the intermediate risk group (good risk:
80.0%, intermediate risk: 21.8%, and poor risk: 44.1%). These
minor differences may be attributed to the smaller sample size of
our study cohort. Similarly, our study also confirmed that patients
with extra-gonadal primary have worse 5-year OS (testicular:
94.7%, retroperitoneal: 83.3%, and mediastinum 75.0%) and
PFS (testicular: 73.0%, retroperitoneal: 22.2%, and mediastinum
33.3%).
Our study confirmed that increased cumulative dose
of cisplatin predisposed patients to both hearing loss and
peripheral neuropathy. In our study, 82% of patients who
received >400mg/m2 of cumulative cisplatin and 38% of those
with ≤400mg/m2 self-reported ototoxicity, which were higher
than those previously reported by Bokemeyer et al. (1998).
In their study, they showed that approximately 20% of TGCT
patients treated with ≤400mg/m2 of cumulative cisplatin and
50% of those who received >400mg/m2 developed hearing
impairment after a median follow-up of 58 months, which
were assessed by pure-tone audiometry (Bokemeyer et al., 1998).
These differences may be explained by the more objective method
of ototoxicity assessment by Bokemeyer and colleagues.
Peripheral neuropathy occurred in 45.5% of our patients, con-
sistent with other studies which showed that 14–43% of TGCT
survivors experience persistent symptomatic peripheral neuropa-
thy after cisplatin-based chemotherapy (Hansen et al., 1989;
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Aass et al., 1990; Bissett et al., 1990; Boyer et al., 1990; Bokemeyer
et al., 1996; Roth et al., 1988; Petersen and Hansen, 1999; von
Schlippe et al., 2001). Our study reported that the odds for
peripheral neuropathy increased by 1.55 times per 100mg/m2
increase in cumulative cisplatin dose, which is similar to those
reported by other studies (Brydoy et al., 2009; Glendenning et al.,
2010). For instance, Glendenning et al. (2010) reported that there
is a 1.91 times higher odds of developing peripheral neuropa-
thy with each 200mg/m2 increase in cumulative cisplatin dose.
Similarly, Brydoy et al. (2009) found that there is a higher preva-
lence of paresthesias following five or more cycles than following
one to four cycles of cisplatin-based chemotherapy in TGCT
survivors. Since peripheral neuropathy is expected to be more
prevalent in an older population, it is not surprising that age was
a significant variable in our regression analysis.
GSTP1, COMT, and TPMT have been implicated in the devel-
opment of cisplatin-induced hearing impairment (Oldenburg
et al., 2007a,b; Ross et al., 2009) and peripheral neuropathy
(Oldenburg et al., 2007a). Ross et al. (2009) demonstrated that
rs12201199 of TPMT (OR = 17.0, 95% CI 2.3, 125.9) and
rs9332377 of COMT (OR = 5.5, 95% CI 1.9, 15.9) are associ-
ated with cisplatin-induced hearing loss in children. Regarding
GSTP1, Oldenburg et al. (2007a,b) found statistically signifi-
cant associations between rs1695 of this gene with peripheral
neuropathy and cisplatin-induced long-term hearing impairment
in TGCT survivors. The A > G polymorphism of rs1695 is a
missense mutation that leads to amino acid change at codon
105 (Ile > Val) (Oldenburg et al., 2007a,b) and may affect the
detoxification capability of this enzyme with chemotherapeutic
agents.
In our study, however, we did not find significant associa-
tions of ototoxicity and peripheral neuropathy with any of our
candidate genes. The following reasons may explain our null
results. First, rs12201199 of TPMT and rs1695 of GSTP1were not
included in the Affymetrix Genome-Wide Human SNP Array 6.0
platform and therefore were not examined. Although one SNP of
TPMT in our study (rs11964408) was in linkage disequilibrium
with rs12201199, its relatively weak linkage with rs12201199,
with a correlation coefficient of 0.65, may explain the lack of
significant association with peripheral neuropathy. Second, we
may have inadequate statistical power due to the small number
of patients in our neurotoxicity cohort (n = 66) to detect such
associations. For instance, the risk for development of ototoxi-
city with rs9332377 of COMT in our study was increased with
an odds ratio of 1.29 (95% CI 0.54, 3.11) similar to that of
Oldenberg and colleague (Ross et al., 2009). However, this asso-
ciation may not have reached statistically significance (P = 0.57)
due to the small sample size of our study. Third, the mechanism
for development of cisplatin-induced ototoxicity may be differ-
ent in adults than in children, and therefore genes other than
COMT and TPMT may be involved. Finally, unlike the studies
by Oldenburg et al. (2007b) and Ross et al. (2009), patients in
our study used a questionnaire instead of audiometric testing to
screen for hearing impairment. As a result, misclassification of
hearing loss may explain our failure to detect any association with
ototoxicity.
The association between SNP rs2073743 of ARVCF and refrac-
tory TGCT should first be replicated in future studies with a
larger number of patients and subsequently validated using a
different patient cohort. In particular, studies to elucidate the
function of the ARVCF gene in the pathogenesis and progres-
sion of TGCT may give insight into development of therapeutic
options in TGCT treatment. If indeed presence of the G/G of the
ARVCF gene SNP rs2073743 is associated with refractory TGCT,
incorporation of this prognostic factor into the IGCCC may be
warranted.
In conclusion, our pilot data suggests that patients with the
G/G genotype of the ARVCF gene SNP rs2073743 may have
increased risk of refractory TGCT after chemotherapy. Although
the underlying mechanism for this increased risk of refractory
disease is unknown, confirmation of the observed association
may have consequences for risk classifications in patients with
metastatic disease and may be of use to select patients who will
benefit from more aggressive treatment at its onset.
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